Short answer: petrelintide (ZP8396) is a long-acting amylin analogue from Zealand Pharma, partnered with Roche, given once weekly. It is the field’s bet that the future is gentler: the Phase 2 ZUPREME-1 trial reported ~10.7% mean weight loss at 42 weeks — more modest than the incretins — but with “placebo-like tolerability” (no vomiting, no GI dropouts at the top effective dose). It is positioned as a foundational therapy, alone or combined with a GLP-1. It has no marketing authorisation anywhere as of mid-2026 and is advancing to Phase 3. New-U does not sell petrelintide. Part of our next obesity-research wave overview.
Plain-English summary. Petrelintide is an unapproved, investigational molecule. The FDA, MHRA and EMA have not authorised it. This page is general information, not legal or medical advice; do not use unapproved compounds on people.
Petrelintide (developmental code ZP8396) is a long-acting amylin analogue — a synthetic version of the satiety hormone amylin, engineered for a long half-life so it can be dosed once a week. Where most of the next wave reaches for more mechanisms, petrelintide deliberately does the opposite: it is a clean, single-pathway amylin drug. Zealand Pharma develops it; in 2025 Roche entered an exclusive collaboration to co-develop and co-commercialise it.
Amylin is co-secreted with insulin from pancreatic beta cells and signals fullness. A long-acting amylin analogue:
It is the same hormone class as cagrilintide, the amylin component inside CagriSema — which is exactly why amylin analogues are studied both as standalone drugs and as combination partners for GLP-1s.
ZUPREME-1 (announced March 2026) was a gender-balanced Phase 2 trial in ~493 people with overweight or obesity, comparing five once-weekly doses of petrelintide against placebo on top of diet and activity. Headlines:
| Metric | Petrelintide (top dose) | Placebo |
|---|---|---|
| Mean weight loss at 42 weeks | up to ~−10.7% | ~−1.7% |
| Vomiting at most effective dose | None reported | — |
| GI-driven discontinuations | None | — |
The investor reaction. ~10.7% is a genuine result, but markets had been primed by incretin numbers in the 20%+ range, so some analysts read ZUPREME-1 as underwhelming on magnitude. The counter-argument is that an amylin drug is not trying to win on raw percentage — it is trying to win on tolerability and durability, as a base layer. Both readings are defensible; the Phase 3 design will test the thesis.
Zealand and Roche position petrelintide as a foundational therapy rather than a maximal one:
| Compound | Mechanism | Pitch | Status |
|---|---|---|---|
| Petrelintide | Amylin only | Gentler, foundational | Phase 3 planned |
| Cagrilintide | Amylin only | Amylin reference / CagriSema component | In combination (CagriSema) |
| CagriSema | Amylin + GLP-1 | Maximal combination | NDA filed |
| Amycretin | Amylin + GLP-1 (one molecule) | Oral + injectable | Phase 3 planned |
Petrelintide is a proprietary Zealand Pharma molecule, not a catalogued reference peptide. New-U does not sell petrelintide. The established, verifiable amylin-analogue research reference is:
It ships as a sealed, lyophilised reference peptide verified to >99% HPLC purity with a per-batch Certificate of Analysis — research use only, not for human consumption.
What is petrelintide?
Zealand Pharma and Roche’s long-acting amylin analogue (ZP8396), dosed once weekly, positioned as a foundational weight-management therapy.
Is petrelintide approved?
No. As of mid-2026 it has no marketing authorisation; it is advancing to Phase 3.
How much weight loss?
~10.7% mean at 42 weeks in ZUPREME-1 — modest versus incretins, but with notably clean GI tolerability.
Why does tolerability matter?
Amylin analogues cause fewer GI side effects, so petrelintide is pitched as a gentler base layer, alone or with a GLP-1.
Can I buy petrelintide for research?
No — it is proprietary. New-U catalogues the amylin reference cagrilintide instead. Research use only.
External links are provided for research reference only; New-U is not affiliated with the cited organisations and links carry no endorsement either way.
New-U Research Compounds catalogues cagrilintide — the long-acting amylin-analogue research reference — as sealed 10-vial packs of lyophilised reference peptide, independently verified by Janoshik and Freedom Diagnostics for >99% HPLC purity, with a per-batch Certificate of Analysis. Research use only — not for human consumption.
View cagrilintide